导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.71% | 1069/4773 |
| 近一周 | -4.22% | 5041/5465 |
| 近一月 | 1.61% | 277/5421 |
| 近一季 | 5.02% | 336/5231 |
| 近半年 | -4.52% | 2849/4920 |
| 近一年 | 11.72% | 998/4394 |
| 近两年 | 107.98% | 566/2954 |
| 近三年 | 58.40% | 484/2253 |
| 成立以来 | 113.93% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
6.21% 275/4961 |
-11.32% 4271/5312 |
- - |
- - |
| 2025 | 44.28% 633/4813 |
9.26% 406/3635 |
8.29% 342/4076 |
19.14% 2182/4524 |
2.36% 982/4813 |
| 2024 | -2.27% 2192/3463 |
-15.54% 2544/2808 |
-4.26% 1487/3014 |
11.16% 2547/3129 |
8.73% 375/3463 |
| 2023 | 11.14% 77/2656 |
8.49% 455/2280 |
0.60% 302/2385 |
-2.07% 618/2515 |
3.98% 40/2655 |
| 2022 | -22.97% 1103/2207 |
-13.67% 811/1919 |
6.25% 740/2016 |
-12.08% 640/2113 |
-4.48% 1891/2208 |
| 2021 | 0.20% 724/1822 |
-5.47% 927/1255 |
9.22% 579/1330 |
-4.56% 720/1466 |
1.68% 838/1822 |
| 2020 | 39.82% 323/1250 |
-8.31% 597/1028 |
13.84% 588/1067 |
17.38% 105/1164 |
14.12% 296/1184 |
| 2019 | 33.37% 434/1092 |
24.00% 537/739 |
-1.63% 316/788 |
1.68% 374/850 |
7.53% 425/918 |
| 2018 | -26.14% 371/834 |
- - |
-8.48% 218/631 |
-2.61% 292/660 |
-11.91% 380/682 |
| 2017 | 17.93% 213/714 |
- - |
- - |
- - |
- - |
| 2016 | -1.95% 124/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方大数据300A VS. 长安沪深300非周期A(740101) |